Navigation Links
Cardium Reports on Third Quarter 2009 Financial Results and Recent Developments
Date:11/10/2009

d to promote a favorable environment for effective wound management by providing a moist protective barrier as well as a micro-scaffold that promotes cell migration and capillary in-growth. The Company plans to develop additional new product opportunities by incorporating other agents into Excellagen formulations, including antimicrobials, DNA and/or other biologics, which are designed to address particular wound healing and other tissue repair applications.

Phase 1/2 Excellarate(TM) Study Published in Wound Repair and Regeneration

Positive findings from the open label multi-center Phase 1/2 Excellarate clinical study were published in the October 2009 issue of Wound Repair and Regeneration, a peer-reviewed journal of the Wound Healing Society. The principal findings of the Phase 1/2 clinical study concluded that Excellarate appeared to be both safe and well tolerated and that complete wound closure was observed at 14 weeks in 10 of the 15 patients (67%), seven of whom had received only a single application of the Excellarate product candidate. In addition, Excellarate appeared to be associated with early rapid healing responses (around half of the patients achieved a 50-99% reduction in wound size by week 2).

Gene Activated Matrix Technology Orthobiologics Initiative

During the third quarter, the Company announced plans to develop a DNA-based orthobiologics product portfolio based on research and development that will initially focus on non-union bone fractures for medically-compromised patients, and spinal fusions for patients with degenerative disc disease. Orthobiologics is a rapidly growing segment of the orthopedics market and represents biologically-active products designed to enhance musculo-skeletal repair and regeneration. The initial orthobiologics focus will be on the development of Osteorate(TM), a DNA-based non-surgical injectable bone graft gel to repair bone fractures
'/>"/>

SOURCE Cardium Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. Cardium Announces $5.3 Million Registered Direct Offering
2. Cardium Completes $5.3 Million Registered Direct Offering
3. Cardiums Corgentin Preclinical Program Shows High Levels of Targeting to Acutely Ischemic Heart Muscle Following Intracoronary Infusion
4. Cardiums InnerCool Therapies Unit Announces European Commercialization Agreement for Portfolio of Temperature Modulation Systems
5. Cardium Reports on Science Channel Series Featuring InnerCools Endovascular Cooling During Brain Surgery at Stanford University
6. Richard A. Schatz, M.D. Joins Cardiums Scientific Advisory Board
7. Cardium Reports on First Quarter 2008 Highlights and Financial Results
8. Cardium Therapeutics Announces Annual Meeting of Stockholders to be Held June 5, 2008
9. Over and Under(R) Pericardium Covered Stent is now in use in England and Proves Great Deliverability
10. Cardium Launches New AWARE Clinical Study Website
11. Cardiums InnerCool Therapies Unit Announces Italian Commercialization Agreement for Portfolio of Temperature Modulation Systems
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/1/2015)... June 1, 2015  Novartis is highlighting data ... CTL019, an investigational chimeric antigen receptor (CAR) T ... treatment of specific types of hard-to-treat non-Hodgkin lymphoma. ... University of Pennsylvania,s Perelman School of Medicine (Penn) ... large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) ...
(Date:6/1/2015)... TRIANGLE PARK, N.C. , June 1, 2015 ... announced the presentation of positive interim results from ... SIOPEL6: A multi-centre open label randomised phase III ... in reducing ototoxicity in patients receiving cisplatin (Cis) ... was presented at the American Society of Clinical ...
(Date:6/1/2015)... Resverlogix Corp. (TSX: RVX) (the "Company") today announced that  ... Congress in London, England in ... BET-Inhibitor, on Key Renal Parameters in Subjects with a ... Post-hoc Analysis of Patients from the ASSERT, SUSTAIN and ... Kalantar-Zadeh , Professor and Chief, Division of Nephrology and Hypertension at University ...
(Date:6/1/2015)... N.Y. , June 1, 2015 /PRNewswire/ ... ) announced today that it has signed ... LLC to co-market their structure-based drug discovery ... As part of the three-year agreement, AMRI ... structure-determination expertise and capabilities. HarkerBIO,s customers will ...
Breaking Biology Technology:Novartis highlights CTL019 data showing its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma 2Novartis highlights CTL019 data showing its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma 3Novartis highlights CTL019 data showing its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma 4Novartis highlights CTL019 data showing its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma 5Novartis highlights CTL019 data showing its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma 6Fennec Announces Presentation Of Positive Interim Sodium Thiosulfate Phase III Safety Data At The 2015 ASCO Annual Meeting 2Fennec Announces Presentation Of Positive Interim Sodium Thiosulfate Phase III Safety Data At The 2015 ASCO Annual Meeting 3Fennec Announces Presentation Of Positive Interim Sodium Thiosulfate Phase III Safety Data At The 2015 ASCO Annual Meeting 4Resverlogix Presents New Data at 52nd Annual European Renal Association - European Dialysis & Transplant Association Congress (ERA-EDTA) 2Resverlogix Presents New Data at 52nd Annual European Renal Association - European Dialysis & Transplant Association Congress (ERA-EDTA) 3Resverlogix Presents New Data at 52nd Annual European Renal Association - European Dialysis & Transplant Association Congress (ERA-EDTA) 4AMRI and HarkerBIO Ink Collaborative Agreement in Buffalo, N.Y. 2AMRI and HarkerBIO Ink Collaborative Agreement in Buffalo, N.Y. 3
... Amicus Therapeutics (Nasdaq: FOLD ) will announce ... of markets on Thursday, May 7, 2009. The results ... and webcast that afternoon at 5 p.m. EDT. Interested ... 5 p.m. EDT by dialing 877-874-1565 (U.S./Canada) or 719-325-4830 ...
... Microfluidics and Imaging -- Net Loss Narrowed by $0.07 per ... (Nasdaq: CALP ) today reported its first quarter ... million compared to $29.3 million in the first quarter of ... 2008 included $2.9 million of revenue related to product lines ...
... of its fifth Best Practices Awards program. Grand Prize winners ... Broad Institute of MIT and Harvard, Genedata, Genentech, GlaxoSmithKline, Merck & ... Research. , ... Needham, Mass (PRWEB) April 29, 2009 ...
Cached Biology Technology:Amicus Therapeutics Announces First Quarter 2009 Financial Results Release Date 2Caliper Life Sciences Reports First Quarter 2009 Results 2Caliper Life Sciences Reports First Quarter 2009 Results 3Caliper Life Sciences Reports First Quarter 2009 Results 4Caliper Life Sciences Reports First Quarter 2009 Results 5Caliper Life Sciences Reports First Quarter 2009 Results 6Caliper Life Sciences Reports First Quarter 2009 Results 7Caliper Life Sciences Reports First Quarter 2009 Results 8Caliper Life Sciences Reports First Quarter 2009 Results 9Caliper Life Sciences Reports First Quarter 2009 Results 10Bio-IT World Announces the Winners of its 2009 Best Practices Awards Program 2Bio-IT World Announces the Winners of its 2009 Best Practices Awards Program 3Bio-IT World Announces the Winners of its 2009 Best Practices Awards Program 4Bio-IT World Announces the Winners of its 2009 Best Practices Awards Program 5Bio-IT World Announces the Winners of its 2009 Best Practices Awards Program 6
(Date:5/11/2015)... May 11, 2015  Through a well-rounded UAS delegation representing ... had a strong showing at AUVSI,s Unmanned 2015 conference last ... Ohio,s UAS industry met with over ... all points along the UAS ecosystem. "Our ... Vice President for Aerospace Rich Knoll . "If you ...
(Date:5/8/2015)... -- Synaptics Inc. (NASDAQ: SYNA ), the leading developer ... executive management team will present at the following investor events: ... Conference Date: May 18, 2015 Time: 10:40am ET ... Cowen and Company Technology, Media & Telecom ... New York Palace Hotel, New York, NY ...
(Date:5/5/2015)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or ... mobile commerce market, reminds investors and media that  Mr. ...  at CARTES SECURE CONNEXIONS AMERICA 2015, held in ... The three-day conference is organized into a series of nine ... Global Fraud: Where is the Trust in Cyberspace? ...
Breaking Biology News(10 mins):Ohio Flies High at Unmanned '15, Sets Stage for Ohio UAS Conference 2Synaptics to Present at Upcoming Investor Conferences 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 3
... Meeting on Acoustics -- a major international acoustics conference ... Coral Beach Hotel in Cancun, Mexico. Reporters are invited ... http://www.acoustics.org/press The press room contains news releases ... more than a thousand presentations at the meeting, which ...
... With so few Americans consuming the recommended amounts of fruit ... fruit servings and the important nutrients they provide ... of 100 percent juice supplies one serving (1/2 cup) of ... New research presented today at the American Dietetic Association (ADA) ...
... UNC scientists describes how cells infected by the Epstein-Barr ... changing their cellular "cargo" of proteins and RNA. This ... of recipient cells from benign to cancer-producing. In ... potentially manipulate other cells throughout the body. The findings ...
Cached Biology News:Worldwide press room opens for major acoustical science and technology conference, Nov. 15-19 2Worldwide press room opens for major acoustical science and technology conference, Nov. 15-19 3Worldwide press room opens for major acoustical science and technology conference, Nov. 15-19 4Worldwide press room opens for major acoustical science and technology conference, Nov. 15-19 5Drinking 100 percent fruit juice is linked to higher intake of essential nutrients 2UNC scientists identify cellular communicators for cancer virus 2
Rabbit polyclonal to GABA A Receptor gamma 2 ( Abpromise for all tested applications). entrezGeneID: 2566 SwissProtID: P18507...
Anti-GOSR2 Monoclonal AntibodyOther Sub-Family: not assigned-Other Applications: Immunocytochemistry, Immunoprecipitation, Western Blot...
... 2/3D Waver Shaker combines shaking and rocking for ... 330 x 330 mm stainless steel or acrylic ... and cold room operation. The platform angle is ... a vigorous with action and rotation speed of ...
... kit for 25 chips provides the chips ... analysis (at picogram levels) with the Experion ... RNA HighSens microfluidic chips, 2 x 1,250 ... RNA HighSens stain, 20 microliters RNA ladder, ...
Biology Products: